In melanomas that were deficient in both IRF1+IRF2, IFN treatment failed to restore the MHC I pathway and reverse the resistance to CPI, indicating that the beneficial effects of the IFN treatment were mediated through the substitutive activity of the transcription factor IRF1. This evidence concerns the gene IRF2 and melanoma.